These two divergent models of liver dysfunction were selected to explore the broad potential application and associated mechanisms of GLP-1 based therapies on various hallmark characteristics of NAFLD, as well as on hepatic regeneration following PH in differing metabolic contexts. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.